“Our collaboration with Kinetiq and Pier Two marks a strategic step in realizing a shared vision for secure, composable, and deeply integrated liquid staking on Hyperliquid,” said Hyunsu Jung, Chief ...

Stuart Therapeutics has reported initial findings from its 29-day randomised Phase III trial of the ST-100 (vezocolmitide) ...

A phase 3 clinical trial investigating ST-100 for the treatment of dry eye disease did not meet its primary endpoint but ...